572 reports of this reaction
3.5% of all ENCORAFENIB reports
#6 most reported adverse reaction
PYREXIA is the #6 most commonly reported adverse reaction for ENCORAFENIB, manufactured by Array BioPharma Inc.. There are 572 FDA adverse event reports linking ENCORAFENIB to PYREXIA. This represents approximately 3.5% of all 16,241 adverse event reports for this drug.
Patients taking ENCORAFENIB who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is moderately reported among ENCORAFENIB users, representing a notable but not dominant share of adverse events.
In addition to pyrexia, the following adverse reactions have been reported for ENCORAFENIB:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 572 FDA reports for ENCORAFENIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 3.5% of all adverse event reports for ENCORAFENIB, making it a notable side effect.
If you experience pyrexia while taking ENCORAFENIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.